Friday brought some good news for Cytokinetics (CYTK) and its experimental heart drug aficamten. The company announced that its Phase 3 trial, dubbed ACACIA-HCM, hit its dual primary endpoints in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). That's a mouthful, but essentially it means the drug helped people with a condition where the heart muscle thickens but doesn't block blood flow, making everyday activities like climbing stairs feel like a marathon.
The data showed that patients taking aficamten saw meaningful improvements in their symptoms and exercise performance compared to those on a placebo. Specifically, over 36 weeks, folks on the drug reported better scores on the Kansas City Cardiomyopathy Questionnaire, which is a standard way to measure how much heart disease is messing with your life. They also showed increased exercise capacity, and these benefits were consistent across all the patient subgroups the researchers looked at.
At the European Society of Cardiology Congress 2026 in Munich, researchers presented an additional analysis that looked at the drug's effects across five key areas: exercise capacity, cardiac structure, cardiac biomarkers, diastolic function, and symptom burden. At the 36-week mark, patients on aficamten showed statistically significant progress in all five categories compared to the placebo group. Even more striking, 53% of treated patients achieved a clinical response in three or more of these areas, while only 13% of the placebo group did the same.
So, a clear win, right? Well, not so fast. The stock market had a different reaction. On Monday, shares of Cytokinetics were down 3.19% at $69.79. Why the sour face? According to Reuters, analysts pointed out that the drug didn't significantly improve heart structure or delay cardiovascular events. Also, about 10% of patients experienced a drop in their heart's pumping capacity, and there were 12 heart failure events during the study.
"Investors might be reacting to the size of the win, not whether it won," Mayank Mamtani, an analyst at B. Riley Securities, told Reuters. That's a fair point. Sometimes a win is a win, but if the market was hoping for a slam dunk, a solid layup might not cut it.
Cytokinetics' Chief Medical Officer, Stephen Heitner, acknowledged the concerns, telling Reuters, "There was an imbalance of heart failure events early on in the study." That's a detail that could give some investors pause, even if the overall results are positive.
The primary data was also published in The New England Journal of Medicine, and the sub-analysis appeared in Circulation, which adds some scientific credibility to the findings. Now, the company is moving forward with plans to file a supplemental New Drug Application with the U.S. Food and Drug Administration in the fourth quarter of 2026 for this specific indication.
So, what's the takeaway? Cytokinetics has a drug that works, but the market is a tough crowd. It's not just about whether a drug works, but how well it works and what the side effects look like. For investors, the next big date to watch is that Q4 FDA submission. If the data holds up and the FDA is convinced, aficamten could be a significant new treatment option for people with nHCM. But for now, the market is saying, "Show me more."
